Sequencing the cancer exome provides valuable information about the coding mutations contributing to tumor progression. Because the exome represents less than 2% of the genome, cancer whole-exome sequencing (WES) using next-generation sequencing (NGS) technology is a cost-effective alternative to whole-genome sequencing (WGS). Cancer exome sequencing also produces a more manageable data set compared to whole-genome approaches.
Cancer researchers can use WES and RNA sequencing to uncover tumor-associated gene expression profiles.
Discovering genetic variants in blood samples using WES is minimally invasive and may help researchers capture predictive or diagnostic cancer biomarkers.
Research into factors associated with cancer susceptibility and early incidence is vital for future translational insights and targetable genes or pathways.
Learn how researchers in Italy perform cancer WES from tumor biopsy samples to better understand the genetic underpinnings of tumor onset and progression, identify biomarkers, and predict response to therapeutic interventions.
Read articleIllumina offers library preparation, sequencing, and data analysis research options for sequencing cancer exomes. Streamlined library prep workflows and flexible kit configurations accommodate multiple study designs. User-friendly tools simplify data analysis.
A high-performance, fast, and complete whole-exome sequencing kit including library prep and hybridization reagents, a comprehensive exome probe panel, clean up/size selection beads, and indexes.
These cost-efficient, user-friendly, mid-throughput benchtop sequencers offer extreme flexibility to support new and emerging applications.
The NovaSeq X Series offers vast application breadth, enabling data-intensive methods at production scale.
Accurate, comprehensive, and efficient analysis of NGS data for a range of applications, including exome as well as genome, transcriptome, and methylome studies.
Discover novel features and benefits with whole-genome sequencing for cancer research.
See how RNA-Seq can reveal information about cancer gene expression and gene fusions that drive tumor progression.
The Cancer Research Methods Guide is a 40+ page comprehensive resource with simple, comprehensive workflows for a broad range of cancer research applications. This guide includes single-cell sequencing, spatial sequencing, methylation profiling, multiomics, cell-free RNA sequencing, and more.
Download free guideA new exome-based test will help determine the genetic variants—germline and somatic—driving these rare cancers.
In this article, Dr. Vivek Subbiah explains how finding a rare biomarker can have a big impact on cancer patients.
Explore the benefits of both approaches to understand which method is best for your research.
Schwarze K, Buchanan J, Taylor JC, Wordsworth, S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018 Oct;20(10):1122-1130. doi: 10.1038/gim.2017.247.